Individual Study / EDILS

Eating Disorders Inventory and Longitudinal Survey
  1. Home
  2. Individual Studies
  3. EDILS

Eating Disorders Inventory and Longitudinal Survey

Networks -
Datasets -
Variables -
Start Year
2015
End Year
2021
Funding
Rouen University Hospital; TARGEDYS SA
Add to cart

Members

Download
Investigators Contacts
  • Dr. David Ribet
    INSERM-University of Rouen
  • Prof. Dr. Pierre Déchelotte
    INSERM-University of Rouen
  • Dr. David Ribet
    INSERM-University of Rouen

Design

Study design
Cohort
Follow Up
Yes, 3 years, ongoing (median 18 months)

Marker Paper

Plasma Peptide Concentrations and Peptide-Reactive Immunoglobulins in Patients with Eating Disorders at Inclusion in the French EDILS Cohort (Eating Disorders Inventory and Longitudinal Survey). Galmiche et al., Nutrients, 2020.

PUBMED 32085628

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
280
Number of participants with biosamples
Supplementary Information
47 M 233 F

Timeline

edils

Selection Criteria
Minimum age
18
Newborns
Twins
Countries
  • France
International/National/Regional (region name)
Regional (Normandie)
Ethnic Origin
Health Status
Supplementary Information
Patients are stratified according to their type of eating disorders (anorexia nervosa, bulimia nervosa, binge eating disorders and eating disorders not otherwise specified). Controls are defined as individuals with BMI between 18.5 and 24.9 and without any diagnosed eating disorder (negative for SCOFF questionnaire)

Recruitment

Sources of recruitment
  • General population
  • Other : Recruitment through clinics and through advertisement (for controls)

Number of participants

Number of participants
289
Number of participants with biosamples
Data Collection Event
Start Date
2015
End Date
2021

Measurements & methods

Dietary intake

yes/no
  • Information collected on habitual food intake collected
  • Special dietary aspects collected (e.g. supplements, probiotics, prebiotics and synbiotics)
Methods
  • Other methods
Other methods
Instrument(s) access
Interview

Alcohol consumption

Information collected
ADOSPA score
Administration method
Self-reported

Tobacco consumption

Questionnaire name/set of questions
Fagerström questionnaire
Administration method
Self-reported

Anthropometric measurements

Weight/height
Measured
Other measurements
Body composition using DEXA and impedencemetry (fat mass, fat free mass), resting energy expenditure using indirect calorimetry

Sociodemographic information

Information collected
Sex,age, residence, marital status, occupation, major life events, etc.
Questionnaire name/set of questions
Set of questions
Administration method
Self-reported

Medication

Information collected
Drug dosage and drug name
Antibiotics
Last treatment and frequency collected
Administration method
Self-reported

Health status

Information collected
Disease diagnosis, clinical data, family history of diseases, comorbidities, etc.
Questionnaire name/set of questions
SCOFF, EDI-2, HAD, BSQ-34, SF-36, QUAVIAM, ORMAN, ROME III
Administration method
Self-reported
Measurements
Weight, height, body mass index, body composition using DEXA and impedencemetry (fat mass, fat free mass), resting energy expenditure using indirect calorimetry

Biological samples and laboratory measurements

Samples collected
Blood, stool
Number of samples
280

Biomarkers

Lipids

Measurement(s)
Various
Medium
Blood

Glucose

Measurement(s)
Various
Medium
Blood

Inflammation markers

Measurement(s)
Various
Medium
Blood

Adiposity biomarkers

Measurement(s)
Various
Medium
Blood

Other biomarkers

Measurement(s)
Ghrelin, autoantibodies against alpha-MSH, autoantibodies against ghrelin
Medium
Blood

Microbiome

Microbial material
16S rDNA (V5-V6)
Number of samples/number of individuals
280
Medium/tissue
Faeces
Sequencing platform
Illumina MiSeq
Preservation method
No; immediate 4°C/-80°C within 24h
Information on type of meal last eaten prior to sample extraction available
no